The meeting and exposition will be held from December 7th through the 10th. Deutsche Bank analyst James Shin has lowered his ...

Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a leading biopharmaceutical firm with a market cap of ...

Tesla remains a significant holding for The Future Fund despite position reductions, according to Managing Partner Gary Black ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

For Q3 2024, Aristotle Atlantic’s Large Cap Growth Composite posted a total return of 1.26% gross of fees, underperforming ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Eli Lilly’s (NYSE: LLY) market isn’t out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a ...

Eli Lilly’s (NYSE: LLY ... on the market now but show an increasing conviction in the $1009 consensus target, a 25% increase from critical support levels. The two revisions tracked within ...

Lilly will also conduct a conference call that ... In these long-term treat-to-target trials, efsitora showed non-inferior A1C reduction compared to the most frequently used daily basal insulins ...

Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for ...

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.